|
AU2002367147A1
(en)
|
2001-12-27 |
2003-07-15 |
Daiichi Pharmaceutical Co., Ltd. |
Beta-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS
|
|
GB0218041D0
(en)
*
|
2002-08-02 |
2002-09-11 |
Merck Sharp & Dohme |
Chemical process
|
|
GB0223039D0
(en)
|
2002-10-04 |
2002-11-13 |
Merck Sharp & Dohme |
Therapeutic compounds
|
|
GB0313772D0
(en)
*
|
2003-06-13 |
2003-07-23 |
Merck Sharp & Dohme |
Therapeutic treatment
|
|
CA2526487A1
(en)
|
2003-06-30 |
2005-01-06 |
Daiichi Pharmaceutical Co., Ltd. |
Heterocyclic methyl sulfone derivative
|
|
WO2005014540A1
(en)
|
2003-08-08 |
2005-02-17 |
Schering Corporation |
Cyclic amine base-1 inhibitors having a heterocyclic substituent
|
|
AU2004265298A1
(en)
|
2003-08-08 |
2005-02-24 |
Pharmacopeia, Inc. |
Cyclic amine BACE-1 inhibitors having a benzamide substituent
|
|
GB0323258D0
(en)
|
2003-10-04 |
2003-11-05 |
Merck Sharp & Dohme |
Therapeutic compounds
|
|
AR047666A1
(es)
|
2004-02-20 |
2006-02-01 |
Merck Sharp & Dohme |
Sintesis estereoselectiva del acido ciclohexanopropanoico 4,4-disubstituido
|
|
AR049726A1
(es)
|
2004-07-22 |
2006-08-30 |
Schering Corp |
Amidas sustituidas inhibidoras de beta secretasa
|
|
AU2006234441B2
(en)
|
2005-04-08 |
2011-07-07 |
Daiichi Sankyo Company, Limited |
Pyridylmethylsulfone derivative
|
|
ATE550019T1
(de)
|
2005-05-17 |
2012-04-15 |
Merck Sharp & Dohme |
Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
|
|
WO2007092435A2
(en)
|
2006-02-07 |
2007-08-16 |
Wyeth |
11-beta hsd1 inhibitors
|
|
US9567396B2
(en)
|
2006-03-07 |
2017-02-14 |
Evonik Degussa Gmbh |
Notch inhibition in the prevention of vein graft failure
|
|
US8133857B2
(en)
|
2006-03-07 |
2012-03-13 |
The Brigham and Women's FHospital, Inc. |
NOTCH inhibition in the treatment of atherosclerosis
|
|
WO2011053822A2
(en)
|
2009-11-01 |
2011-05-05 |
The Brigham And Women's Hospital, Inc. |
Notch inhibition in the treatment and prevention of obesity and metabolic syndrome
|
|
AU2008215948A1
(en)
|
2007-02-12 |
2008-08-21 |
Merck & Co., Inc. |
Piperazine derivatives for treatment of AD and related conditions
|
|
TW200920362A
(en)
|
2007-09-11 |
2009-05-16 |
Daiichi Sankyo Co Ltd |
Alkylsulfone derivatives
|
|
CA2709677C
(en)
|
2007-12-21 |
2017-03-14 |
Lin Zhi |
Selective androgen receptor modulators (sarms) and uses thereof
|
|
CA2707447C
(en)
*
|
2007-12-26 |
2016-03-08 |
Banyu Pharmaceutical Co., Ltd. |
Sulfonyl-substituted 6-membered ring derivative
|
|
EP2291181B9
(en)
|
2008-04-18 |
2013-09-11 |
University College Dublin National University Of Ireland, Dublin |
Captodiamine for the treatment of depression symptoms
|
|
WO2010114780A1
(en)
|
2009-04-01 |
2010-10-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of akt activity
|
|
WO2011046771A1
(en)
|
2009-10-14 |
2011-04-21 |
Schering Corporation |
SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
|
|
US8999957B2
(en)
|
2010-06-24 |
2015-04-07 |
Merck Sharp & Dohme Corp. |
Heterocyclic compounds as ERK inhibitors
|
|
AU2011285909B2
(en)
|
2010-08-02 |
2016-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
|
|
EP4079856A1
(en)
|
2010-08-17 |
2022-10-26 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
|
|
WO2012030685A2
(en)
|
2010-09-01 |
2012-03-08 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
|
EP2615916B1
(en)
|
2010-09-16 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel erk inhibitors
|
|
EP3327125B1
(en)
|
2010-10-29 |
2020-08-05 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
|
|
US9351965B2
(en)
|
2010-12-21 |
2016-05-31 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
|
WO2013059302A1
(en)
|
2011-10-17 |
2013-04-25 |
Nationwide Children's Hospital, Inc. |
Products and methods for aortic abdominal aneurysm
|
|
EP2770987B1
(en)
|
2011-10-27 |
2018-04-04 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
|
EP3453762B1
(en)
|
2012-05-02 |
2021-04-21 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
|
AU2013323508B2
(en)
|
2012-09-28 |
2017-11-02 |
Merck Sharp & Dohme Corp. |
Novel compounds that are ERK inhibitors
|
|
EP2925888B1
(en)
|
2012-11-28 |
2017-10-25 |
Merck Sharp & Dohme Corp. |
Compositions and methods for treating cancer
|
|
CA2895504A1
(en)
|
2012-12-20 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as hdm2 inhibitors
|
|
EP2951180B1
(en)
|
2013-01-30 |
2018-05-02 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
US9708253B2
(en)
*
|
2014-01-06 |
2017-07-18 |
Bristol-Myers Squibb Company |
Cyclohexyl sulfone RORγ modulators
|
|
EP3094323A4
(en)
|
2014-01-17 |
2017-10-11 |
Ligand Pharmaceuticals Incorporated |
Methods and compositions for modulating hormone levels
|
|
EP3525785B1
(en)
|
2016-10-12 |
2025-08-27 |
Merck Sharp & Dohme LLC |
Kdm5 inhibitors
|
|
EP3706742B1
(en)
|
2017-11-08 |
2023-03-15 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
|
US11098059B2
(en)
|
2017-11-08 |
2021-08-24 |
Merck Sharp & Dohme Corp. |
PRMT5 inhibitors
|
|
EP3823672A1
(en)
|
2018-07-19 |
2021-05-26 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Combination for treating cancer
|
|
US11981701B2
(en)
|
2018-08-07 |
2024-05-14 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
|
WO2020033288A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
|
EP3833668B1
(en)
|
2018-08-07 |
2025-03-19 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
|
CA3133929A1
(en)
|
2019-04-19 |
2020-10-22 |
Lin Zhi |
Crystalline forms and methods of producing crystalline forms of a compound
|
|
US20230108452A1
(en)
|
2019-12-17 |
2023-04-06 |
Merck Sharp & Dohme Llc |
Prmt5 inhibitors
|
|
WO2021126728A1
(en)
|
2019-12-17 |
2021-06-24 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
|
WO2021126729A1
(en)
|
2019-12-17 |
2021-06-24 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
|
EP4244391A1
(en)
|
2020-11-16 |
2023-09-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating uveal melanoma
|
|
PE20251401A1
(es)
|
2022-09-02 |
2025-05-22 |
Merck Sharp And Dohme Llc |
Inhibidores de topoisomerasa-1 derivados de exatecan composiciones farmaceuticas y sus usos
|
|
AU2023366166A1
(en)
|
2022-10-25 |
2025-05-01 |
Merck Sharp & Dohme Llc |
Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
|
|
WO2024129628A1
(en)
|
2022-12-14 |
2024-06-20 |
Merck Sharp & Dohme Llc |
Auristatin linker-payloads, pharmaceutical compositions, and uses thereof
|